\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes Horizon EuropeThe budget for the next European framework programme for research and innovation Horizon Europe 2021-2027, will be around €95.5 billion in current prices. Part of this budget is coming from Next Generation EU, €5.4 billion in current prices, and €4.5 billion in current prices comes from among others fines for breaking EU competition law.
The political agreement, reached on 11 December, between the German Presidency of the Council and the negotiators of the European Parliament for the proposed regulation establishing Horizon Europe, will still have to be formally approved by the Council and European Parliament. The regulation can only be formally adopted after the formal adoption of the EU's long-term budget, the Multi Financial Framework for 2021-2027.
European Commission press release
Science Business article ‘EU announces budget breakdown for Horizon Europe after 14-hour talks’
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
